Sirtris Pharmaceuticals to Present at Keystone Symposia's Diabetes Mellitus, Insulin Action and Resistance Conference
January 23 2008 - 7:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, announced today
that a member of its Scientific Advisory Board and two of its
scientists will be presenting at the Keystone Symposia�s Diabetes
Mellitus, Insulin Action and Resistance Conference in Breckenridge,
Colorado January 22-27. The presentations will include data on the
impact of a new chemical activator of SIRT1, an enzyme shown to
increase insulin sensitivity and improve glucose levels when
stimulated in pre-clinical models of Type 2 Diabetes. Johan Auwerx,
MD, PhD, a member of Sirtris� Scientific Advisory Board and
Professor at the Medical Faculty of the University of Strasburg and
Co-director of the Mouse Clinical Institute (ICS) in Strasburg,
France, will speak during the session on New Molecular Mechanisms
of Insulin Resistance. His talk will be on Saturday, January 26
from 8-11:30 am CST. Professor Auwerx will present new data that
includes the impact of one of Sirtris� new chemical entities (NCEs)
in mice on a high-fat diet. Heidi Galonek, PhD of Sirtris
Pharmaceuticals will present her poster titled Small Molecule
Activators of SIRT1 Suppress Inflammatory Signaling Pathways In
Vivo on Wednesday, January 23 from 7:30-10:00 pm CST. �This work,
which also used one of Sirtris� new chemical entities, suggests
SIRT1 activators could address the chronic low grade inflammation
associated with Type 2 Diabetes,� said Michael Jirousek, PhD,
Senior Vice President of Research. �In addition, we demonstrated
that we could improve insulin sensitivity and glucose
homeostatsis.� Jesse Smith, PhD, also of Sirtris Pharmaceuticals,
will present his poster titled Small Molecule Activators of SIRT1
Mimic Calorie Restriction In Vivo: A Novel Therapeutic Strategy in
Treating Type II Diabetes on Friday, January 25 from 7:30-10:00 pm
CST. �This work demonstrates that small molecules can mimic aspects
of calorie restriction (CR) and provides further understanding of
the mechanisms at work,� said Jirousek. �In a blinded analysis,
databases at a computational systems biology company concluded that
the strongest hypothesis for the results seen in our study was
calorie restriction�showing that our novel SIRT1 activators are
mimicking the effects of calorie restriction.� "Sirtris is
dedicated to building a broad platform of sirtuin therapeutics for
diseases of aging,� said Sirtris Chief Executive Officer and Vice
Chair Christoph Westphal, MD, PhD. �Our research program is
continuously progressing new chemical entities toward the clinic
with the first NCE planned to enter human trials in the first half
of 2008." About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is
a biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, the potential therapeutic effects of SIRT1
activators for diseases of aging, such as Type 2 Diabetes; the
progress and results of pre-clinical studies of new chemical
entities and pre-clinical and clinical studies of SIRT1 activators;
development of first-in-class therapeutics known as new chemical
entities that modulate sirtuins; and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of
Sirtris Pharmaceuticals involve significant risks, uncertainties
and assumptions, including risks related to the lack of results
that would provide a basis for predicting whether any of the
Company's product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results,
the Company's potential inability to initiate and complete
pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of the
Company to gain market acceptance of the Company's product
candidates, and those other risks factors that can be found in the
Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles